GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.16
Bid: 3.52
Ask: 4.80
Change: 0.16 (4.00%)
Spread: 1.28 (36.364%)
Open: 4.00
High: 0.00
Low: 0.00
Prev. Close: 4.00
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proteome Sciences 2019 Loss Narrows On Revenue Jump

Tue, 14th Apr 2020 14:30

(Alliance News) - Proteome Sciences PLC on Tuesday reported a sharply narrowed loss for 2019, as revenue grew substantially on the achievement of higher sales.

For the year, the protein biomarker research company posted a pretax loss of GBP36,000 compared to GBP1.7 million the year before, as administrative expenses fell to GBP2.7 million from GBP3.3 million.

Revenue however, increased by 53% to GBP4.7 million from GBP3.0 million the prior year, as year-on-year sales and royalties attributable to tandem mass tag sales grew by 68% to GBP3.7 million from GBP2.2 million.

Meanwhile, proteomics services revenue rose by 24% to around GBP930,000 from GBP750,000.

Looking ahead, Proetome Services said it is operating as usual despite the Covid-19 pandemic, with new orders from clients received and a strong cash position.

The company expects to sustain and further improve its financial performance in 2020.

"The launch of 16plex TMTpro in the summer was well received and is expected to contribute significantly in 2020. Our strategy of more direct customer engagement in the US market resulted in significant increases in quotes issued and orders received, particularly in the fourth quarter," said Interim Chief Executive Officer Ian Pike.

"With high levels of work carried over from 2019 we have made a good start to 2020, though significant uncertainty may result because of the impact of the coronavirus pandemic. Currently there are no issues with supply chains, or our staffing levels and the majority of samples required for ongoing projects have already been received in Frankfurt," Pike added.

Shares in Proteome Sciences were down 5.2% at 4.06 pence on Tuesday in London.

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
23 Jun 2015 13:26

Proteome raises £2.5m from placing

Protein biomarker company Proteome Science has placed 13.86m shares at 18p each, raising £2.5m before expenses. The proceeds will be used to increase capacity and shorten lead times ensuring the company can continue to meet the significant increase in demand for its biomarker services from a growing

Read more
23 Jun 2015 06:59

Proteome Sciences Raises GBP2.5 Million In Share Placing (ALLISS)

Read more
29 May 2015 08:01

Proteome Sciences Says It Has Seen "Good Start" To 2015, Loss Widens

Read more
9 Mar 2015 08:40

Proteome Sciences Sees Good Start To 2015 On Contract Signings

Read more
12 Nov 2014 13:06

UK MIDDAY BRIEFING: RBS, HSBC Hit With Fines, Barclays Still In Talks

Read more
12 Nov 2014 12:02

UK WINNERS & LOSERS: G4S And Tullow Oil Lead FTSE 100 Gainers

Read more
12 Nov 2014 12:00

Proteome slides after warning on revenues

Shares in Proteome fell sharply on Wednesday after the group warned its revenue for the current year will be lower than market expectations and "somewhat" lower than the revenues achieved in 2013. The protein biomarker group explained that it had seen a continuation of the previously flagged delay t

Read more
12 Nov 2014 09:27

Proteome Says Revenue Will Not Meet Market Expectations

Read more
30 Sep 2014 09:41

Proteome Appoints Geoffrey Ellis As Finance Director, Loss Widens

Read more
26 Sep 2014 07:21

UK MORNING BRIEFING: De La Rue, Shanks Issue Profit Warnings

Read more
26 Sep 2014 07:03

Proteome Sees "Excellent" Toxicity Test Results For Alzheimer's Drugs

Read more
25 Sep 2014 15:29

Proteome Sciences wins $2m biomarker deal

teerngasAIM biotech Proteome Sciences has been signed up to provide to develop diagnostic products for Alzheimer's disease group Genting TauRx Diagnostic, worth $2m in upfront and milestone payments. Proteome's biomarker services division will analyse blood samples from patients enrolled in a phase

Read more
25 Sep 2014 12:15

REPEAT: UK MIDDAY BRIEFING: Glaxo Appoints Philip Hampton As Next Chairman

Read more
25 Sep 2014 12:09

UK MIDDAY BRIEFING: Glaxo Appoints Ex-RBS Head As Non-Exec Chairman

Read more
25 Sep 2014 11:43

UK WINNERS & LOSERS: 5G Deal Boosts Vodafone Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.